ReviewMolecular medicine (Cambridge, Mass.)2025
Nerve growth factor: what can surgeons and oncologists learn from a neurological and psychological biomarker?
Review in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The neuronal network of small cell lung cancer: a narrative review of the role of the nervous system in the pathogenesis and progression.Translational lung cancer research · 2026Review
- Cytokines and cancer-associated fibroblasts.Journal of hematology & oncology · 2026Review
- The neuro-vascular-immune triad: the interactive network in the tumor microenvironment.Cell communication and signaling : CCS · 2026Review
- NGF-mediated tumor-stroma crosstalk promotes prostate cancer aggressiveness.Journal of translational medicine · 2026Article
- Article
- The Neuro-Bone Axis in Metastatic Progression: Innervation, Neuro-Immune-Osteoclast Crosstalk, and Therapeutic Opportunities.Biology · 2026Review
- The influence of neuro-tumor interactions on tumorigenesis and therapeutic response.Experimental hematology & oncology · 2026Review
- Neurotrophin NGF/TrkA and BDNF/TrkB signaling orchestrates the immune microenvironment in osteosarcoma.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAs the first discovered member of the neurotrophin family, nerve growth factor (NGF) plays fundamental roles in peripheral sensory and sympathetic neuronal development and survival. Recent evidence reveals its tumour-promoting effects through increasing perineural invasion, which is correlated with poor clinical outcomes. The exact molecular mechanisms exhibit malignancy-specific differences and remain incompletely characterized. MAIN TEXT: This review compares mechanistic insights and therapeutic advancements regarding NGF signalling in neurological/psychological disorders with discoveries in oncological contexts. Functioning as a dual biomarker for neural integrity and pathological progression, NGF primarily exerts its effects via an interaction with the high-affinity tyrosine kinase receptor. Both molecules are frequently overexpressed in malignant tissues. NGF orchestrates tissue regeneration and tumourigenesis through the activation of conserved neurotrophin pathways and downstream proliferative cascades, some of which participate in regulating the expression and secretion of NGF in turn. In practical applications, in addition to acting as an antiproliferative target, NGF could be utilized in psychological management, antinociceptive treatment, and wound healing.
conclusionsSystemic NGF-targeted therapies have significant articular and neurological toxicity, indicating the critical need for localized intervention strategies depending on the expression level of NGF and TrkA to balance antitumour efficacy with protective requirements for nerve structures and innervation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.